Statin therapy in metabolic syndrome and hypertension post-JUPITER: What is the value of CRP?

Sridevi Devaraj, David Siegel, Ishwarlal Jialal

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Much evidence supports a pivotal role for inflammation in atherosclerosis. C-reactive protein (CRP), the prototypic marker of inflammation in humans, is a cardiovascular risk marker and may also promote atherogenesis. CRP levels are increased in metabolic syndrome and hypertension and confer increased risk of cardiovascular events in patients in these subgroups. Statins have been shown to lower low-density lipoproteins and CRP independently, and reduce cardiovascular events in subjects with and without metabolic syndrome and hypertension. In this review, we focus on the results from the primary prevention statin trial, Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), which showed reductions in LDL, CRP, and cardiovascular events. Post-JUPITER, the new guidelines will now need to consider recommending high-sensitivity CRP testing to intermediate-risk metabolic syndrome patients and those with hypertension and intermediate risk so that we can better identify candidates at greater risk and reduce cardiovascular burden in these subjects with statin therapy.

Original languageEnglish (US)
Pages (from-to)31-42
Number of pages12
JournalCurrent Atherosclerosis Reports
Issue number1
StatePublished - Feb 2011


  • Atherosclerosis
  • CRP
  • Endothelial dysfunction
  • Hypertension
  • Inflammation
  • Metabolic syndrome
  • Monocytes
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Statin therapy in metabolic syndrome and hypertension post-JUPITER: What is the value of CRP?'. Together they form a unique fingerprint.

Cite this